BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 8777471)

  • 1. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.
    Ruilope LM; Simpson RL; Toh J; Arcuri KE; Goldberg AI; Sweet CS
    Blood Press; 1996 Jan; 5(1):32-40. PubMed ID: 8777471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
    Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J
    Clin Ther; 1996; 18(4):608-25. PubMed ID: 8879890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.
    Townsend R; Haggert B; Liss C; Edelman JM
    Clin Ther; 1995; 17(5):911-23. PubMed ID: 8595643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
    Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
    Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan potassium as initial therapy in patients with severe hypertension.
    Dunlay MC; Fitzpatrick V; Chrysant S; Francischetti EA; Goldberg AI; Sweet CS
    J Hum Hypertens; 1995 Nov; 9(11):861-7. PubMed ID: 8583463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
    Manolis AJ; Grossman E; Jelakovic B; Jacovides A; Bernhardi DC; Cabrera WJ; Watanabe LA; Barragan J; Matadamas N; Mendiola A; Woo KS; Zhu JR; Mejia AD; Bunt T; Dumortier T; Smith RD
    Clin Ther; 2000 Oct; 22(10):1186-203. PubMed ID: 11110230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    Goldberg AI; Dunlay MC; Sweet CS
    Am J Cardiol; 1995 Apr; 75(12):793-5. PubMed ID: 7717281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.
    Rosenstock J; Rossi L; Lin CS; MacNeil D; Osbakken M
    J Clin Pharm Ther; 1998 Dec; 23(6):433-40. PubMed ID: 10048504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
    Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
    Edes I;
    Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.
    Gradman AH; Brady WE; Gazdick LP; Lyle P; Zeldin RK
    Clin Ther; 2002 Jul; 24(7):1049-61. PubMed ID: 12182251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
    Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
    Clin Ther; 2010 Jul; 32(7):1252-69. PubMed ID: 20678674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.
    Soffer BA; Wright JT; Pratt JH; Wiens B; Goldberg AI; Sweet CS
    Hypertension; 1995 Jul; 26(1):112-7. PubMed ID: 7607713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension.
    Flack JM; Saunders E; Gradman A; Kraus WE; Lester FM; Pratt JH; Alderman M; Green S; Vargas R; Espenshade M; Ceesay P; Alexander J; Goldberg A;
    Clin Ther; 2001 Aug; 23(8):1193-208. PubMed ID: 11558858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
    Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
    Benz JR; Black HR; Graff A; Reed A; Fitzsimmons S; Shi Y
    J Hum Hypertens; 1998 Dec; 12(12):861-6. PubMed ID: 9883710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
    Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K
    Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy.
    Suh SY; Ahn T; Bae JH; Lim DS; Lee SU; Kim YK; Hyon MS; Kim WH; Han KR; Park HK
    Clin Ther; 2014 Oct; 36(10):1402-11. PubMed ID: 25146365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
    Volpe M; Christian Rump L; Ammentorp B; Laeis P
    Clin Drug Investig; 2012 Oct; 32(10):649-64. PubMed ID: 22909147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.